A lawsuit was filed on February 12, 2015 by Cheri Flynn from Minnesota, against pharmaceutical giant GlaxoSmithKline (GSK). In her complaint, Flynn alleged that taking Zofran for her severe morning sickness led to two of her children developing heart defects. For summaries of the complaint, click here. This lawsuit is just one of many lawsuits filed against GSK, each of which allege that Zofran caused severe child birth defects in babies delivered by mothers who took Zofran during the first trimester for severe morning sickness.
"Ms Flynn took Zofran during the first trimester of two pregnancies," explains Michael Monheit, Esq., from Monheit Law. "The complaint points to several studies that suggest an association between Zofran and certain severe child birth defects."
The first child being referred to in the case, B.F., was born in 2004. The child was premature and was diagnosed with a congenital heart defect. Furthermore, B.F. suffered various developmental delays as a consequence of being premature and the heart defect. The child had to undergo heart surgery in 2011, whereby her septal defect (hole in the heart) was repaired. Her second child, T.F., was born two years later, also prematurely. This child also had a heart defect and she required around the clock monitoring to ensure her oxygen levels were appropriate. As a result, she also suffered from significant developmental delays.
During the first and second pregnancies, a physician had prescribed Zofran to Ms. Flynn, as she suffered from severe morning sickness. According to the complaint, she was not warned about any risks of taking Zofran, neither from her doctor, nor from GSK directly. Additionally, there is no indication of congenital heart defects in Ms. Flynn's family history. Furthermore, she was tested for genetic anomalies and all tests came back clear. Ms. Flynn has also stated that she would not have agreed to take Zofran had she been aware of the risks to her unborn children's health.
Various Zofran related lawsuits are currently being filed against GSK. Various damages are being identified, including economic and non-economic loss, pain and suffering, medical expenses, emotional pain, punitive damages and loss of consortium. Naturally, each of the cases against GSK are unique, as the circumstances and facts in each case are different. It remains to be seen as to how the litigation will play out, however discovery in the first filed cases is likely to commence soon and more information will likely be made public.
Zofran? is a drug that prevents nausea and vomiting. It has been FDA approved to alleviate the sickness that people experience after surgery, or while undergoing chemotherapy. However, it has been prescribed "off-label" to women who are experiencing hyperemesis gravidarum and NVP, which are medical terms for morning sickness.
Michael Monheit - 1-877-620-8411 - firstname.lastname@example.org
1368 Barrowdale Road
Rydal, PA 19046
Source URL: http://www.pressadvantage.com/story/587
Release ID: 78010